Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 29, 2021 - Issue 3
Submit an article Journal homepage
265
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Treatment of Refractory Cystoid Macular Edema with Pegylated Interferon Alfa-2A: A Retrospective Chart Review

Hillary C. Stiefela Department of Ophthalmology, Portland VA Health Care System, Portland, OR, USA;b Departments of Ophthalmology (Casey Eye Institute), Oregon Health & Science University, Portland, OR, USAView further author information
, MD,
Laura J. Kopplina Department of Ophthalmology, Portland VA Health Care System, Portland, OR, USA;b Departments of Ophthalmology (Casey Eye Institute), Oregon Health & Science University, Portland, OR, USA;c Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, WI, USAView further author information
, MD, PhD,
Thomas Albinid Bascom Palmer Eye Institute, University of Miami, Miami, FL, USAView further author information
, MD,
Michael Changa Department of Ophthalmology, Portland VA Health Care System, Portland, OR, USA;e Hospital and Specialty Medicine, Oregon Health & Science University, Portland, OR, USAView further author information
, MD,
Sravanthi Veguntad Bascom Palmer Eye Institute, University of Miami, Miami, FL, USA;f John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USAView further author information
, MD &
Eric B. Suhlera Department of Ophthalmology, Portland VA Health Care System, Portland, OR, USA;b Departments of Ophthalmology (Casey Eye Institute), Oregon Health & Science University, Portland, OR, USACorrespondence[email protected]
View further author information
, MD, MPH
Pages 566-571 | Received 16 Nov 2018, Accepted 28 Oct 2019, Published online: 19 Nov 2019

References

  • Lardenoye C, Van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113:1446–1449. doi:10.1016/j.ophtha.2006.03.027.
  • Yalçindağ FN, Uzun A. Results of interferon alpha-2a therapy in patients with Behcet’s disease. J Ocul Pharmacol Ther. 2012;28(4):439–443. doi:10.1089/jop.2011.0238.
  • Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol. 2011;129(3):288–294. doi:10.1001/archophthalmol.2011.3.
  • Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144:55–61. doi:10.1016/j.ajo.2007.03.050.
  • Fardeau C, Simon A, Rodde B, et al. Interferon-alpha2a and systemic corticosteroid in monotherapy in chronic uveitis: results of the randomized controlled BIRDFERON study. Am J Ophthalmol. 2017;177:182–194. doi:10.1016/j.ajo.2017.03.001.
  • Deuter C, Kotter I, Gunaydin I. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906–913. doi:10.1136/bjo.2008.153874.
  • Deuter C, Kotter I, Gunaydin I, et al. Interferon alfa-2a: A new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26:786–791. doi:10.1097/01.iae.0000244265.75771.71.
  • Lightman S, Taylor SRJ, Bunce C, et al. Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet’s disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis. 2015;74(6):1138–1144. doi:10.1136/annrheumdis-2014-205571.
  • Bielefeld P, Devilliers H, Deschasse C, et al. Potential of pegylated interferon alpha-2a in Behçet uveitis: a report of five cases. Ocul Immunol Inflamm. 2015;24:1–4. doi:10.3109/09273948.2015.1010652.
  • Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335–339. doi:10.1136/bjo.2006.101550.
  • Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol. 2013;156(3):478–486. doi:10.1016/j.ajo.2013.05.002.
  • Taraborelli M, Cavazzana I, Fredi M, et al. Treatment and functional outcome of patients with cystoid macular edema: a single-center experience. Clin Rheumatol. 2015;34(4):791–794. doi:10.1007/s10067-014-2694-z.
  • Levin MH, Pistilli M, Daniel E, et al. Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology. 2014;121(2):588–595. doi:10.1016/j.ophtha.2013.09.023.
  • Tranos PG, Tsaousis KT, Vakalis AN, et al. Long-term follow-up of inflammatory cystoid macular edema. Retina. 2012;32(8):1624–1628. doi:10.1097/IAE.0b013e3182483348.
  • Deuter C, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet’s disease. Arthritis Rheum. 2010;62:2796–2805. doi:10.1002/art.27581.
  • Agarwal SK, Bhowmik D, Mahajan S, et al. Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study. Indian J Nephrol. 2016;26(4):244–251. doi:10.4103/0971-4065.172228.
  • Liu CH, Liang CC, Lin JW, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomized study. Gut. 2008;57:525–530. doi:10.1136/gut.2007.133884.
  • Goncalves LL, Farias AQ, Goncalves PL, et al. Branch retinal vein thrombosis and visual loss probably associated with pegylated intereferon therapy of chronic hepatitis C. World J Gastroenterol. 2006;12(28):4602–4603. doi:10.3748/wjg.v12.i28.4602.
  • Manesis EK, Petrou C, Brouzas D, et al. Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol. 1994;21:474–477. doi:10.1016/S0168-8278(05)80331-9.
  • Ayaki M. Development of neovascular glaucoma in the course of interferon alfa therapy for hepatitis type C. Br J Ophthalmol. 1994;78(3):238. doi:10.1136/bjo.78.3.238-a.
  • Panetta JD, Gilani N. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection. Ailment Pharmacol Ther. 2009;30(6):597–602. doi:10.1111/apt.2009.30.issue-6.
  • Soushi S, Kobayashi F, Obazawa H, et al. Evaluation of risk factors of interferon-associated retinopathy in patients with type C chronic active hepatitis. J Jpn Ophthalmol Soc. 1996;100(1):69–76.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.